Biogen BIIB
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Biogen (BIIB) Business Model and Operations Summary
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
Key Insights
Biogen (BIIB) Core Market Data and Business Metrics
Latest Closing Price
$132.03Market Cap
$19.43 BillionPrice-Earnings Ratio
11.93Total Outstanding Shares
146.38 Million SharesTotal Employees
7,605Dividend
No dividendIPO Date
September 17, 1991SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
225 Binney Street, Cambridge, MA, 02142
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Operating Activities, Continuing | $2.13 Billion |
| Net Cash Flow, Continuing | $-643.30 Million |
| Net Cash Flow From Financing Activities | $-1.34 Billion |
| Exchange Gains/Losses | $54.60 Million |
| Net Cash Flow | $-588.70 Million |
| Net Cash Flow From Financing Activities, Continuing | $-1.34 Billion |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Benefits Costs and Expenses | $7.70 Billion |
| Revenues | $9.61 Billion |
| Income Tax Expense/Benefit | $291.70 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $-800,000 |
| Net Income/Loss Attributable To Parent | $1.62 Billion |
| Selling, General, and Administrative Expenses | $2.33 Billion |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss | $1.63 Billion |
| Other Comprehensive Income/Loss Attributable To Parent | $13.60 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $-800,000 |
| Comprehensive Income/Loss Attributable To Parent | $1.63 Billion |
| Other Comprehensive Income/Loss | $13.60 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Other Current Liabilities | $4.71 Billion |
| Inventory | $2.47 Billion |
| Liabilities | $11.95 Billion |
| Equity Attributable To Parent | $16.36 Billion |
| Intangible Assets | $9.81 Billion |
| Wages | $288.70 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||